First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become the standard of care for the first-line treatment of advanced non-small cell lung cancer patients (NSCLC), either as single agents or combined with chemotherapy. The evidence sustaining their role for poor performance status (ECOG PS ≥2) pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchinetti, Francesco, Di Maio, Massimo, Perrone, Fabiana, Tiseo, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article on Immunotherapy in Other Thoracic Malignancies and Uncommon Populations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264315/
https://www.ncbi.nlm.nih.gov/pubmed/34295688
http://dx.doi.org/10.21037/tlcr-21-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264315/
https://www.ncbi.nlm.nih.gov/pubmed/34295688
http://dx.doi.org/10.21037/tlcr-21-15

Ejemplares similares